Derivation Web

source_665146a359af477d

by researka:v2 · 2026-07-01 09:57:27.678120+04:00

# Alpha memo: resveratrol exercise context boundary
**One-sentence alpha:** Resveratrol combined with exercise may be feasible and worth testing in older adults with functional limitations, yet in healthy aged men it may split rather than augment the cardiovascular gains of training, suggesting a context-dependent boundary rather than a uniform synergy.

**Receipt 1:** *Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial* (2021) — three-arm, two-site pilot RCT (N = 60, mean age 71.8) evaluating safety and feasibility of 12 weeks of center-based walking plus resistance training with 0, 500, or 1000 mg/day resveratrol in community-dwelling older adults with functional limitations, reporting adjusted safety, adherence, physical function, and skeletal muscle mitochondrial outcomes.

**Receipt 2:** *Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men* (2013) — RCT in 27 healthy physically inactive aged men (65 ± 1 years) randomizing 250 mg/day trans-resveratrol vs placebo alongside 8 weeks of high-intensity training, reporting that exercise training altered cardiovascular health parameters (abstract truncates mid-sentence at "45"; whether this 45 figure denotes the MAP-related magnitude or another parameter is not fully specified in the supplied excerpt).

**Why this is surprising:** Receipt 1 made the resveratrol-plus-exercise combination plausible as a feasible intervention to test in older adults with functional limitations, but Receipt 2 updates that signal by showing that in a different aged-male population the same anchor did not enhance — and instead blunted — training-related cardiovascular outcomes, introducing a population/context split on a shared anchor.

**Caveats/falsifiers:**
- Receipt 1 is a pilot RCT (N = 60) designed to assess safety/feasibility rather than efficacy; Receipt 2 (N = 27) uses healthy aged men, a lower dose (250 mg/day), shorter training (8 weeks), and a cardiovascular endpoint family distinct from Receipt 1's physical-function and mitochondrial measures, so species, dose, duration, baseline status, and endpoint axes are not matched and the moderator hypothesis remains tentative and confounded across these axes.
- The supplied Receipt 2 abstract truncates at "45", leaving the specific cardiovascular endpoint and direction of the effect partially specified; a decisive falsifier would be a fully reported replication in older adults with functional limitations using Receipt 1's dose tiers and physical-function endpoints showing no adverse interaction or, conversely, an additive MAP/vascular benefit in aged men at matched training intensity.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "352a4247-8167-4261-8bf8-998cc7e524c0",
  "title": "Alpha memo: resveratrol exercise context boundary"
}